• Intra-Cellular Therapies average return on tangible equity for 2023 was -27.68, a 41.38% decline from 2022.
• Intra-Cellular Therapies average return on tangible equity for 2022 was -47.22, a 6.59% decline from 2021.
• Intra-Cellular Therapies average return on tangible equity for 2021 was -44.3, a 15% increase from 2020.

Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.